PUBLICATION AND CONFIDENTIALITY. 8.1 It is the policy of FOUNDATION and Cornell to promote and safeguard free and open inquiry by faculty, students and others. To further this policy, FOUNDATION and Cornell shall retain the right to publish information described in Applications and Patents. 8.2 Both parties agree to keep any information identified as confidential by the disclosing party confidential using methods at least as stringent as each party uses to protect its own confidential information, except as may be necessary to maintain an action against LICENSEE for breach of this Agreement or to audit LICENSEE as specified under Section 5.8. “Confidential Information” shall include the progress report required under Section 4.7 and any other information marked confidential or accompanied by correspondence indicating such information is confidential exchanged between the parties hereto. The confidentiality and use obligations set forth above apply to all or any part of the Confidential Information disclosed hereunder except to the extent that:
Appears in 4 contracts
Samples: Exclusive License Agreement (Pacific Biosciences of California, Inc.), Exclusive License Agreement (Pacific Biosciences of California Inc), Exclusive License Agreement (Pacific Biosciences of California Inc)
PUBLICATION AND CONFIDENTIALITY. 8.1 It is the policy of FOUNDATION and Cornell to promote and safeguard free and open inquiry by faculty, students and others. To further this policy, FOUNDATION and Cornell shall retain the right to publish information described in Applications and Patents.
8.2 Both parties agree Each Party agrees to keep any information identified as confidential by the disclosing party Party confidential using methods at least as stringent as each party Party uses to protect its own confidential information, except as may be necessary to maintain an action against LICENSEE for breach of this Agreement or to audit LICENSEE as specified under Section 5.85.7. “Confidential Information” shall include the progress report required under Section 4.7 4.8 and any other information marked confidential or accompanied by correspondence indicating such information is confidential exchanged between the parties heretoParties hereunder. The confidentiality and use obligations set forth above apply to all or any part of the Confidential Information disclosed hereunder except to the extent that:
Appears in 2 contracts
Samples: Exclusive License Agreement (Stealth BioTherapeutics Corp), License Agreement (Stealth BioTherapeutics Corp)
PUBLICATION AND CONFIDENTIALITY. 8.1 It is the policy of FOUNDATION INSTITUTIONS and Cornell to promote and safeguard free and open inquiry by faculty, students and others. To further this policy, FOUNDATION INSTITUTIONS and Cornell shall retain the right to publish information described in Applications and Patents.
8.2 Both parties All Parties agree to keep any information identified as confidential by the disclosing party confidential using methods at least as stringent as each party Party uses to protect its own confidential information, except as may be necessary to maintain an action against LICENSEE for breach of this Agreement or to audit LICENSEE as specified under Section 5.85.9. “Confidential Information” shall include the progress report required under Section 4.7 4.10 and any other information marked confidential or accompanied by correspondence indicating such information is confidential exchanged between the parties hereto. The confidentiality and use obligations set forth above apply to all or any part of the Confidential Information disclosed hereunder except to the extent that:
Appears in 1 contract
Samples: Exclusive License Agreement (Stealth BioTherapeutics Corp)
PUBLICATION AND CONFIDENTIALITY. 8.1 It is the policy of FOUNDATION and Cornell to promote and safeguard free and open inquiry by faculty, students and others. To further this policy, FOUNDATION and Cornell shall retain the right to publish information described in Applications and Patents.
8.2 Both parties agree Each Party agrees to keep any information identified as confidential by the disclosing party Party confidential using methods at least as stringent as each party Party uses to protect its own confidential information, except as may be necessary to maintain an action against LICENSEE for breach of this Agreement or to audit LICENSEE as specified under Section 5.85.6. “Confidential Information” shall include the progress report required under Section 4.7 4.9 and any other information marked confidential or accompanied by correspondence indicating such information is confidential exchanged between the parties heretoParties hereunder. The confidentiality and use obligations set forth above apply to all or any part of the Confidential Information disclosed hereunder except to the extent that:
Appears in 1 contract
Samples: Exclusive License Agreement (Stealth BioTherapeutics Corp)
PUBLICATION AND CONFIDENTIALITY. 8.1 It is the policy of FOUNDATION and Cornell to promote and safeguard free and open inquiry by faculty, students and others. To further this policy, FOUNDATION and Cornell shall retain the right to publish information described in Applications and Patents.
8.2 Both parties agree Each Party agrees to keep any information identified as confidential by the disclosing party Party confidential using methods at least as stringent as each party Party uses to protect its own confidential information, except as may be necessary to maintain an action against LICENSEE for breach of this Agreement or to audit LICENSEE as specified under Section 5.85.6. “Confidential Information” shall include the progress report required under Section 4.7 4.8 and any other information marked confidential or accompanied by correspondence indicating such information is confidential exchanged between the parties heretoParties hereunder. The confidentiality and use obligations set forth above apply to all or any part of the Confidential Information disclosed hereunder except to the extent that:
Appears in 1 contract
Samples: Exclusive License Agreement (Stealth BioTherapeutics Corp)